Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02135's EV-to-FCF is ranked better than 94.61% of 408
companies
in the Healthcare Providers & Services industry
Industry Median: 18.7
vs HKSE:02135: 1.98
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Raily Aesthetic Medicine International Holdings (HKSE:02135) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Raily Aesthetic Medicine International Holdings's PE Ratio (TTM) for today is calculated as:
Raily Aesthetic Medicine International Holdings's share price for today is HK$0.119.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Raily Aesthetic Medicine International Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Raily Aesthetic Medicine International Holdings EV-to-FCF Related Terms
Raily Aesthetic Medicine International Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings EV-to-FCF Chart
Raily Aesthetic Medicine International Holdings Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raily Aesthetic Medicine International Holdings EV-to-FCF vs Healthcare Providers & Services Industry
Raily Aesthetic Medicine International Holdings's current Enterprise Value is HK$55.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Raily Aesthetic Medicine International Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$27.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings (HKSE:02135) has a EV-to-FCF of 2.04 as of Aug. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. According to the industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #22 out of 408 companies in the Healthcare Providers & Services industry, placing it in the top 5.4%.
Is Raily Aesthetic Medicine International Holdings' EV-to-FCF too high?
Raily Aesthetic Medicine International Holdings' current EV-to-FCF is 2.04. The Healthcare Providers & Services industry median EV-to-FCF is 18.70. Raily Aesthetic Medicine International Holdings' value of 2.04 is 89.1% below this industry median. Based on the distribution chart, Raily Aesthetic Medicine International Holdings ranks #22 out of 408 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Raily Aesthetic Medicine International Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raily Aesthetic Medicine International Holdings' EV-to-FCF compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #22 out of 408 companies for EV-to-FCF. This places Raily Aesthetic Medicine International Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.70. Raily Aesthetic Medicine International Holdings' value of 2.04 is 89.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.70, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raily Aesthetic Medicine International Holdings's current EV-to-FCF of 2.04 is 89.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raily Aesthetic Medicine International Holdings's current EV-to-FCF is 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raily Aesthetic Medicine International Holdings stock overvalued right now?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings (HKSE:02135) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.12 — trading 15% below its estimated fair value. The current EV-to-FCF is 2.04 and 89.1% below the Healthcare Providers & Services industry median of 18.70. Raily Aesthetic Medicine International Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Raily Aesthetic Medicine International Holdings (HKSE:02135), the current EV-to-FCF is 2.04 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raily Aesthetic Medicine International Holdings (HKSE:02135) Overvalued in 2026?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings stock appears to be undervalued.
The current stock price of HK$0.12 is trading 15% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Raily Aesthetic Medicine International Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:02135:
EV-to-FCF: 2.04
GF Value™: HK$0.14 vs. price of HK$0.12 (15% below fair value)
Industry Position: 89.1% below the Healthcare Providers & Services median (#22 of 408)
No single metric tells the full story. See the HKSE:02135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raily Aesthetic Medicine International Holdings Ltd is an investment holding company. The company were principally engaged in the provision of aesthetic medical services, sale of aesthetic medical equipment products and provision of consulting services. The group is organized into three reportable operating segments namely Aesthetic medical services comprise principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others; Aesthetic medical equipment products comprise principally sales of collagen injection products, surgical implants and aesthetic medical skincare products; Consulting services comprise principally management consulting services of which majority of revenue comes from Aesthetic medical services.
47GF Score
Get the complete analysis for HKSE:02135
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02135 has been successfully added to your 
